Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
Authors
Christine Megerdichian Parseghian
The University of Texas MD Anderson Cancer Center, Houston, TX
Christine Megerdichian Parseghian , Jessica Kim Lee , Julia Quintanilha , Alexa B. Schrock , Ryon Graf , Lincoln Pasquina , Smruthy Sivakumar , Geoffrey R. Oxnard , Hanna Tukachinsky , Samuel J. Klempner , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 199)
DOI
10.1200/JCO.2024.42.3_suppl.199
Abstract #
199
Poster Bd #
M7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.
First Author: Brendon Fusco
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2023 ASCO Annual Meeting
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.
First Author: Pashtoon Murtaza Kasi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay.
First Author: Reagan Barnett